Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2869047/0/en/Iovance-Biotherapeutics-to-Present-Clinical-and-Translational-Data-at-2024-ASCO-Annual-Meeting.html

SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, will be highlighted at the upcoming 2024 ASCO Annual Meeting to be held May 31- June 4, 2024, at McCormick Place in Chicago, IL and online.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.